Formal approval for Keytruda looks to make life difficult for some anti-PD-(L)1 latecomers.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.
After a frothy couple of years, biotechs are no longer seeing big boosts from clinical data.
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
July and August saw key regulatory and clinical developments for several anti-PD-(L)1 MAbs, with plenty more in store for oncology watchers.
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.